~//bj.watch/overview
live

concept dossier

Algorithmic Health

Algorithmic health is the pattern of using measurement systems, scientific priors, and algorithmic rules to choose health behavior instead of relying on mood, cravings, social defaults, or introspection. bryan johnson's blueprint protocol is the clearest current example in this wiki: he describes shifting authority from “what sounded good” to body/organ data, with his mind not authorized to override the algorithm.

healthprotocolbiomarkersautomationdecision

// Habits · Longterm · Don’ts

Algorithmic Health: habits, longterm, and don’ts

Three buckets keep practical routines, long-range interpretation, and source-aware caution visible on every protocol surface.

repeatable behaviors

Habits

  • Run the measurement loop: bloodwork, wearables, oral/skin/organ metrics, then retest instead of relying on vibes.concepts/blueprint-protocol.md
  • Keep the stable inputs visible first: consistent sleep, training, nutrient-dense meals, oral care, light exposure, and recovery.concepts/blueprint-protocol.md
durable strategy

Longterm

  • Treat Blueprint as a repeatable feedback system whose rules can evolve as biomarkers, symptoms, or evidence change.concepts/blueprint-protocol.md
  • Track the June 2026 sauna/HSP27 thread as a protocol-design case study: Johnson shifted the dose question from minutes in the sauna to measured core temperature and biomarker response.raw/articles/bryan-johnson/x-twitter-daily-2026-06-17.md
  • Treat the July 2026 sauna checklist as Johnson’s attributed protocol guidance. Its 4–7-session frequency, heat-dose targets, fertility and microplastics claims, hydration advice, and environmental cautions are not a reader prescription or independent evidence of longevity benefit.raw/articles/bryan-johnson/x-twitter-daily-2026-07-24.md
  • Track the June 2026 jet-lag follow-up as a self-reported caffeine + melatonin test using blood glucose as a body-clock readout, not as general travel medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md
  • Treat the June 2026 Australian sun/skin-aging post as a skin-readout example inside the measurement loop, not as validated skincare advice.raw/articles/bryan-johnson/x-twitter-daily-2026-06-20.md
  • Treat the June 2026 Immortals Rx expansion separately from foundational habits; the GLP-1, SGLT2, peptide, and NAD+ catalog is a commercial/protocol claim that requires clinician oversight.raw/articles/bryan-johnson/x-twitter-daily-2026-06-23.md
  • Treat the July 2026 six-option GLP-1 catalog as an Immortals Rx commercial update. Johnson names branded and compounded listings, but the post does not establish formulation status, availability, prescribing criteria, or safety and efficacy for longevity use.raw/articles/bryan-johnson/x-twitter-daily-2026-07-23.md
  • Treat Johnson’s August 2026 Viagra-plus-statins cancer-spread post as a low-confidence intervention claim. He identifies the cited work as preclinical and the human evidence as observational; his proposed extension from sildenafil to tadalafil is not evidence of efficacy or a reason to combine medicines.raw/articles/bryan-johnson/x-twitter-daily-2026-08-04.md
  • Treat Johnson’s June 2026 “one international trip per quarter” rule as a biomarker-derived personal boundary, not as a reader travel guideline.raw/articles/bryan-johnson/x-twitter-daily-2026-06-24.md
  • Treat the June 2026 inherited-cancer DNA + RNA panel as germline risk-stratification context, not a diagnosis, universal screening recommendation, or validation of Johnson’s early-surveillance statistics.raw/articles/bryan-johnson/x-twitter-daily-2026-06-26.md
  • Treat the July 2026 AIG single-cell immune-receptor sequencing thread as Johnson’s diagnostic follow-through: a cellular/receptor-level measurement layer, not a validated therapy or reader test recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-04.md
  • Treat the July 2026 low-ferritin / Monoferric follow-up as Johnson’s self-reported AIG case and false-negative philosophy, not a general iron-infusion recommendation.raw/articles/bryan-johnson/x-twitter-daily-2026-07-08.md
  • Treat the July 2026 AIG cure roadmap and “Bryan in a dish” model as a proposed personal experiment; it is not an approved autoimmune-disease cure, validated ex-vivo screening protocol, or reader treatment pathway.raw/articles/bryan-johnson/x-twitter-daily-2026-07-09.md
  • Treat the July 2026 Kate Tolo endometriosis workup as multi-modality diagnostic-triangulation context; it is not a reader diagnostic pathway, independent validation, or proof that endometriosis can now be cured.raw/articles/bryan-johnson/x-twitter-daily-2026-07-10.md
  • Read Johnson’s July 2026 “removing harm” list as a subtraction-first behavior philosophy. Sleep consistency, movement, avoiding nicotine/alcohol, and reducing obvious hazards belong with foundations; the post does not quantify each item or resolve the safety and attribution questions around his intervention stack.raw/articles/bryan-johnson/x-twitter-daily-2026-07-11.md
  • Treat the July 2026 Kate Tolo 90-day / 1,900-biomarker announcement as a projected N=1 program specification, not completed female-health evidence, a representative protocol, or medical advice.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Treat Johnson’s RHR “Sovereignty Index” as within-person behavior-design framing. His reported 41 bpm average is not a universal target, and resting heart rate needs individual and clinical context.raw/articles/bryan-johnson/x-twitter-daily-2026-07-16.md
  • Treat the July 2026 ocular tear-panel post as an organ-specific measurement plan. Johnson reports a $1,800 specialty-lab panel across 15 biomarkers, but publishes no result, diagnosis, clinical utility, intervention, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-22.md
  • Treat Immortals’ July 2026 disease-resolution infrastructure expansion as Johnson’s strategy and product positioning. The iPSC, organoid, deep-cell-characterization, and personalized-therapy directions do not establish an operational clinical platform, diagnosis, treatment, cure, safety, or outcome.raw/articles/bryan-johnson/x-twitter-daily-2026-07-25.md
  • Treat the July 2026 operational Kate Tolo baseline as an N=1 measurement program. The 100-day, 14-million-data-point plan with 100+ daily tasks, 50+ devices, and a 12-person team is not completed evidence, a representative female-health protocol, or reader guidance.raw/articles/bryan-johnson/x-twitter-daily-2026-07-26.md
  • Treat Johnson’s August 2026 claim that Kate Tolo’s protocol was built in 90 days and is “better” than his five-year build as an operational comparison only. No quality criteria, comparative measurements, outcomes, or external validation were published.raw/articles/bryan-johnson/x-twitter-daily-2026-08-05.md
  • Treat Johnson’s August 2026 47-tube, 250 mL blood draw as a scale and methods update. The post names single-cell immune sequencing and broad measurement domains but publishes no assay list, results, diagnosis, clinical interpretation, or evidence that collection volume improves outcomes.raw/articles/bryan-johnson/x-twitter-daily-2026-08-13.md
  • Treat Johnson’s August 2026 interval-training post as an attributed exercise claim, not a prescription. The 4×4 shape (3 sessions/week, 4 minutes at 90–95% effort with 3 easy minutes, 8 weeks) is the Helgerud et al. 2007 protocol (+7.2% VO2max), and the “11% lower all-cause mortality” figure compresses per-MET fitness associations (Kodama et al. 2009: 13% lower all-cause mortality per MET, RR 0.87)—no trial has measured mortality from eight weeks of intervals, and the post names no study.https://x.com/bryan_johnson/status/2092230490581574033
  • Treat Johnson’s August 2026 LDL post as an attributed cholesterol claim. The “49 trials, 312,175 people, ~23% fewer major vascular events per 39 mg/dL” figure matches Sabatine et al. 2016 (JAMA; RR 0.77 per 1 mmol/L), and the “13–14% over six months” diet figure matches the Jenkins et al. 2011 portfolio-diet RCT (−13.1% to −13.8% LDL from viscous fiber, nuts, plant protein, and plant sterols)—but the post names neither study, and trial-population relative effects are not individual guarantees or a lab-interpretation directive.https://x.com/bryan_johnson/status/2092597711543632216
  • Treat Johnson’s August 2026 NTE-by-age decline tables as an attributed normative-data claim. The age-related decline is documented (Karacan et al. 1975 normative NPT series; Schiavi et al. 1988; Horita & Kumamoto 1989: 189.6 min at age 20 declining to ~62 min at 70, nearly matching his age-20 anchor), but the post names no study, its intermediate bins match no single published cohort, and the repeated “2x risk in 4 years” outruns meta-analytic averages—not a validated risk prediction or monitoring recommendation.https://x.com/bryan_johnson/status/2093698799172829255
  • Treat Johnson’s August 2026 Kernel brain-scan percentile post as an attributed self-report. The regional percentiles (amygdala 95th, putamen 99th, caudate 97th, frontal gray matter 78th “and climbing”), heritability figures, and personality mappings are his own account against an undisclosed normative cohort; the plasticity literature he gestures at (Draganski et al. 2004: transient visual-motion-cortex gray-matter change from juggling; Colcombe et al. 2006: frontal-volume gains from aerobic exercise in older adults) does not validate region-by-region self-interpretation—not a brain-health metric, evidence the protocol grew his frontal cortex, or medical advice.https://x.com/bryan_johnson/status/2094112145357291863
  • Treat Johnson’s August 2026 nighttime-erection post as an attributed N=1 biomarker claim. ED does precede and predict cardiovascular events (Vlachopoulos et al. 2011 JACC meta-analysis: RR 1.48 CVD, 1.35 stroke; Krimpen cohort: HR 2.6 only for severely reduced rigidity), but his flat “2x risk in 4 years” outruns the meta-analytic averages, the post names no study, consumer NTE scores are not a validated clinical risk tool, and daily tadalafil 5 mg is a prescription medication requiring clinician oversight—not a reader protocol.https://x.com/bryan_johnson/status/2093061998468903267
  • Treat the Baseten biological-age event as public measurement positioning. Its brain, skin, strength, balance, reaction-speed, and mobility domains are not evidence that the tests form a validated or actionable biological-age score.raw/articles/bryan-johnson/x-twitter-daily-2026-08-14.md
  • Treat the August 2026 meibomian-gland post as an attributed N=1 diagnosis-and-intervention account. Johnson reports advanced MGD with gland dropout, a four-therapy stack (IPL, radiofrequency, intraductal probing, 630nm red light), and a self-reported 30% gland-function improvement; his own post says the probing science is unsettled and the therapies cannot be separated. It is not a validated eye-care protocol or reader guidance.https://x.com/bryan_johnson/status/2089822905891000605
  • Preserve medical-caution framing: this page summarizes Johnson/Blueprint practice, not personal treatment advice.concepts/biomarker-driven-longevity-protocols.md
guardrails

Don’ts

  • Do not present N=1 biomarker movement as proof of clinical outcomes.concepts/biomarker-driven-longevity-protocols.md
  • Do not mix experimental drugs, hormones, or supplements into the same confidence tier as sleep, exercise, and food quality.concepts/blueprint-protocol.md

Algorithmic Health

Algorithmic health is the pattern of using measurement systems, scientific priors, and algorithmic rules to choose health behavior instead of relying on mood, cravings, social defaults, or introspection. bryan johnson’s blueprint protocol is the clearest current example in this wiki: he describes shifting authority from “what sounded good” to body/organ data, with his mind not authorized to override the algorithm.

Components

  • Dense measurement: biomarkers, organ-specific age proxies, sleep, fitness, inflammation, fertility, and environmental/toxin data.
  • Evidence ranking: clinical literature and power-law prioritization of interventions.
  • Delegated decision authority: diet, sleep, exercise, and advanced therapies are selected by protocol rather than desire.
  • Iterative feedback: interventions are re-scored and modified as data changes.
  • Public protocolization: results are shared as routines, products, apps, leaderboards, and community challenges.

Johnson’s May 26, 2026 posts show the same pattern applied to mundane constraints. Sun exposure becomes a skin-aging and vitamin-D-management problem; international travel becomes a glucose, circadian, and sleep-architecture recovery problem; Kate Tolo’s female-protocol baseline becomes a reason to avoid international travel during measurement. The dashboard should label the specific travel recovery timelines as Johnson’s attributed N=1 claims unless corroborated elsewhere.

The June 17 Nature/N-of-1 essay turns the same pattern into a methodology claim. Johnson and the Blueprint & Immortals science team describe AI, wearables, multi-omics, real-time tracking, and exposome data as tools for mapping individualized response and eventually positioning less-measured people against deeply measured pioneers. That is algorithmic health at platform scale: data collection first, model/neighbor inference second, and individualized decisions last. The claim is useful as a design pattern, but the biological examples bundled with it remain unvalidated self-experiment signals.

In a July 11 post responding to Nassim Nicholas Taleb’s interaction-risk critique, Johnson described removing harm as his “best performing longevity therapy.” His list included sleep deprivation and inconsistent timing, sedentary behavior, alcohol, nicotine, late-night eating, excess sugar and fat, loneliness, poor air and water, and several broader or less-defined exposures. This adds a useful subtraction-first branch to algorithmic health: remove obvious negative inputs before optimizing additions. It does not quantify each item’s contribution, validate broad counts such as “15,000 chemicals,” or answer the confounding and interaction questions raised by his remaining intervention stack.

On July 14, Johnson gave this decision pattern a named score: Resting Heart Rate as his “Sovereignty Index.” He reported a personal 41 bpm 30-day average and argued that pre-sleep RHR reflects whether engineered consumption and a stressed evening self are controlling behavior. His checklist—stop food four hours before bed, stop screens 60 minutes before bed, keep one bedtime, wind down deliberately, finish caffeine by noon, and use red/amber rather than blue evening light—is a classic algorithmic-health move: decide the rules before willpower is lowest. The useful signal is the pre-commitment model, not 41 bpm as a goal. RHR varies with fitness, illness, medication, stress, physiology, and measurement conditions; Johnson’s value and broad vagal-tone claims are self-report and should not be read as diagnosis or medical advice.

On July 23, Johnson supplied a miniature feedback-loop example: he reported that finishing food at 2 p.m. rather than noon moved his sleep heart rate from 42 to 44 bpm, then compared the sensitivity to changes in EV charging, aerodynamics, and coffee-grinder settings. The algorithmic-health signal is the habit of treating a small input change as something to measure and retest. One personal comparison does not isolate meal timing from confounders, establish clinical importance, or turn noon into a reader target.

On August 16, Johnson made the same rule explicit in a sensitive food-control context. Responding to people who characterize his dietary control as an eating disorder, he described discipline as mastery, said he changes his food protocol according to data, and acknowledged that the pursuit can become unhealthy. This sharpens both the delegated-decision-authority pattern and its risk boundary. It is Johnson’s personal self-description and rhetorical argument; it does not establish clinical appropriateness, decide whether a behavior is disordered, or show that his regimen generalizes.

On September 1–2, a cafe’s caffeinated-instead-of-decaf mistake became the pattern’s most public miniature. Johnson first reported that the error wrecked his sleep and made him cancel morning dunk training, citing that “acute sleep disruption can increase injury risk by 70-130%.” Two days later he returned to the cafe with a sound meter and published the investigation: ~75 dBA background noise against his replicated 72 dBA order volume (a −3 dB signal-to-noise ratio in which “a decaf coffee” and “a cup of coffee” could sound nearly identical even with healthy hearing), a photographed order screen where adjacent and otherwise-identical “brewed” buttons invite a “capture error,” a cited roughly 1-in-8 cafe order error rate, and an estimated ~55% chance the barista recognized him. The useful signal is the forensic habit itself—quantifying a mundane mistake with decibels, error rates, and base rates rather than dismissing it. The boundary is the injury figure: it names no study, and the nearest literature measures something else. Chronic insufficient sleep in adolescent athletes raises injury risk 1.7× on multivariate analysis (Milewski et al., 2014, J Pediatr Orthop; 112 athletes, <8 h/night; RR 2.1 univariate), and rising training load with falling sleep raises it up to 2.25× (von Rosen et al., 2017, Scand J Med Sci Sports; 496 athletes)—season-long associations in young athletes, not acute single-night disruption in a 49-year-old. Skipping one session after a wrecked night is a defensible personal decision; the specific number is not a validated statistic, and none of it is sleep guidance or medical advice.

On September 4, Johnson gave the “Autonomous Health” thesis its first named product instantiation. He announced an AI model built on sleep data—developed with Eight Sleep, available on their platforms—that reads a “sleep fingerprint” from a bed sensor, identifies a sleeper from one night’s signal (92.5%), estimates biological age within 3.3 years, and flags conditions from diabetes to sleep apnea, closing that “a passive, daily activity like sleep can now provide meaningful insight into your well-being” in “a world where the things around us take care of us without our knowing or asking.” That is algorithmic health with the human removed from the measurement loop entirely: no device to wear, no test to order—the bed does the sensing and the model does the interpretation. The verification picture is unusually good for this feed: the post’s figures match a real preprint (BCG-FM, Kjaer et al., arXiv:2606.07692: 2.04M hours from 136,575 participants; 3.26-year MAE; diabetes 0.852, heart failure 0.822 external, hypertension 0.810, sleep apnea 0.792 AUROC; R²=0.982 batch scaling). The boundary is equally structural: the model is vendor-trained and vendor-evaluated behind a membership feature co-developed with Johnson’s Immortals, its internal disease labels are self-reported, the preprint is unreviewed, and the post’s “better than Apple’s model” comparison does not appear in the paper—whose Apple-Watch benchmark is age accuracy, not disease detection. Johnson’s own post calls it “a research milestone, not a diagnostic device.” The dashboard records an attributed product-launch and research claim with verified preprint context—not a validated ambient diagnostic, a reason to treat a mattress number as clinical information, or medical advice.

Why it matters

The pattern mirrors broader AI-agent and automation themes already in the wiki: humans externalize memory, evaluation, and decision procedures into tool loops. In health, the upside is consistency and measurement discipline; the downside is overfitting to proxies, expensive N=1 intervention stacks, and social/psychological rigidity.

Evaluation checklist

  • Are target metrics clinically meaningful or merely measurable?
  • Are recommendations robust across sex, age, disease state, and baseline fitness?
  • Is there a clear separation between high-confidence basics and experimental therapies?
  • Who audits the algorithm, the evidence ranking, and conflicts of interest?